Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
During Q2 2025, the RiverPark Large Growth Fund (Institutional Class) returned 15.01%, lagging the Russell 1000 Growth Index's 17.84% but outperforming the S&P 500's 10.94%. The quarter was...
— Brent Jackson
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Eli Lilly and Company
The company remains a premier growth compounder in the highly underserved global diabetes and obesity therapeutic markets. While the market...
Eli Lilly is the eleventh largest holding. Global branded pharmaceutical...
Eli Lilly is a global pharmaceutical leader commanding major commercial franchises in diabetes, metabolic dysfunction, oncology, immunology, and neuroscience. The manager initiated...